Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Current perspectives on statins
Autore:
Maron, DJ; Fazio, S; Linton, MF;
Indirizzi:
Vanderbilt Univ, Sch Med, Dept Med, Div Cardiovasc Med, Nashville, TN 37232 USA Vanderbilt Univ Nashville TN USA 37232 ovasc Med, Nashville, TN 37232 USA
Titolo Testata:
CIRCULATION
fascicolo: 2, volume: 101, anno: 2000,
pagine: 207 - 213
SICI:
0009-7322(20000118)101:2<207:CPOS>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
COA REDUCTASE INHIBITORS; CORONARY HEART-DISEASE; SCANDINAVIAN-SIMVASTATIN-SURVIVAL; LOW-DENSITY-LIPOPROTEIN; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; AVERAGE CHOLESTEROL LEVELS; LIPID-LOWERING THERAPY; NITRIC-OXIDE SYNTHASE; MYOCARDIAL-INFARCTION; COMBINATION THERAPY;
Keywords:
statins; hypercholesterolemia; trials; atherosclerosis; coronary disease;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
75
Recensione:
Indirizzi per estratti:
Indirizzo: Maron, DJ Vanderbilt Univ, Sch Med, Dept Med, Div Cardiovasc Med, 315 Med Res Bldg 2, Nashville, TN 37232 USA Vanderbilt Univ 315 Med Res Bldg 2 Nashville TN USA 37232 32 USA
Citazione:
D.J. Maron et al., "Current perspectives on statins", CIRCULATION, 101(2), 2000, pp. 207-213

Abstract

Statins (HMG-CoA reductase inhibitors) are used widely for the treatment of hypercholesterolemia. They inhibit HMG-CoA reductase competitively, reduce LDL levels more than other cholesterol-lowering drugs, and lower triglyceride levels in hypertriglyceridemic patients. Statins are well tolerated and have an excellent safety record. Clinical trials in patients with and without coronary heart disease and with and without high cholesterol have demonstrated consistently that statins reduce the-relative risk of major coronary events by approximate to 30% and produce a greater absolute benefit in patients with higher baseline risk. Proposed mechanisms include favorable effects on plasma lipoproteins, endothelial function, plaque architecture andstability, thrombosis, and inflammation. Mechanisms independent of LDL lowering may play an important role in the clinical benefits conferred by these drugs and may ultimately broaden their indication from lipid-lowering to antiatherogenic agents.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 06:50:54